Loading stock data…
$35.42-0.64 (-1.77%)
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Indivior Pharmaceuticals, Inc. in the Healthcare sector is trading at $35.42 with a market capitalization of $4.5B. Wall Street consensus targets $49.00 (4 analysts), implying a +38.3% move over the next 12 months. The stock is currently 17% below its 52-week high of $42.81, remaining 0.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $343.00M↑ | $317.00M↓ | $358.00M↑ | $314.00M↑ | $302.00M |
| Gross Profit | $293.00M↑ | $277.00M↓ | $291.00M↑ | $231.00M↓ | $250.00M |
| Operating Income | $159.00M↑ | $137.00M↑ | $83.00M↑ | $44.00M↓ | $71.00M |
| Net Income | $122.00M↑ | $89.00M↓ | $102.00M↑ | $42.00M↑ | $18.00M |
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Can...